

WHO Model List of Essential Medicines (EML)

A collaborative review of cancer medicines by the Union for International Cancer Control (UICC) and the World Health Organization (WHO)

2015 WHO MODEL LIST OF ESSENTIAL MEDICINES REVIEW

WHO Model List of Essential Medicines

Updated every two years by a dedicated Expert Committee since its inception in 1977, the WHO Model List of Essential Medicines (EML) provides an internationally recognisable set of selected medicines to help countries choose how to treat their priority health needs.

A new partnership in support of the expert committee process

A series of monthly discussions between WHO and UICC in 2014 resulted in a coordinated plan to review medicines for the treatment of specific cancers. The UICC convened a team of experts to review the standard anti-neoplastic treatment regimens for 29 diseases and generated new evidence-based proposals for addition of essential cancer medicines to the WHO EML.

The proposals were considered by a specially convened WHO Working Group on New Cancer Medicines responsible for reviewing consistency of approach and evidence synthesis.


WHO EML Secretariat and UICC

Cancers included were those for which the goal of systemic treatment is cure or long-term remission (even if low incidence), and cancers with high incidence where treatment produces a clinically relevant survival benefit.

A new disease-based format was agreed between the EML Secretariat and UICC with specific emphasis given to the relevance of benefit as demonstrated by the available evidence as a guiding principle to identify the medicines to be proposed for EML inclusion.

The result was a **proposed list of 52 essential cancer medicines** to be considered by the WHO Expert Committee on Selection and Use of Essential Medicines. **22 of these medicines had not previously been included** on the WHO EML.

WHAT'S NEW



- Policy makers and cancer planners have a foundation on which to base their national EMLs in response to the NCD Global Action Plan target of 80% availability of essential medicines and technologies for NCDs by 2025
- The update facilitates volume prediction and allow for supply chain planning and strengthening

18
New types of cancer can be treated

WHO Model EML for Adults 19th edition

New cancer medicines added: 16
New diseases addressed: 11
Cancer medicines total: 46
Diseases addressed total: 29

WHO Model EML for Children 5th edition

New cancer medicines added: 10
New diseases addressed: 7
Cancer medicines total: 26
Diseases addressed total: 10


WAY FORWARD

A process and timelines for continuous update of the WHO EML cancer section is being elaborated by WHO, with UICC's support

The WHO and UICC approved a disease-based framework to be used for future reviews of the cancer section of the WHO EML

UICC will encourage policy makers and cancer planners in countries to use this framework at national level

EVOLUTION OF THE WHO MODEL EML FOR CANCER MEDICINES



ADDITIONS IN 2015

Adults 19th edition

- | | |
|--|--|
| Anastrozole
Early stage breast cancer
Metastatic breast cancer | Filgrastim
Primary and secondary prophylax. neutropenia
Chemotherapy facilitator |
| ATRA
Acute promyelocytic leukemia | Fludarabine
Chronic lymphocytic leukemia |
| Bendamustine
Chronic lymphocytic leukemia
Follicular lymphoma | Gemcitabine
Epithelial ovarian cancer
Non-small cell lung cancer |
| Bicalutamide
Metastatic prostate cancer | Oxaliplatin
Early stage colon cancer
Metastatic colorectal cancer |
| Capecitabine
Early stage colon cancer
Early stage rectal cancer
Metastatic breast cancer
Metastatic colorectal cancer | Rituximab
Chronic lymphocytic leukemia
Diffuse large b-cell lymphoma
Follicular lymphoma |
| Imatinib
Chronic myeloid leukemia
Gastrointestinal stromal tumour | Trastuzumab
Early stage her2+ breast cancer
Metastatic her2+ breast cancer |
| Irinotecan
Metastatic colorectal cancer | Vinorelbine
Early stage breast cancer
Metastatic breast cancer |
| Cisplatin
Cervical cancer
Head and neck cancer
Non-small cell lung cancer
Osteosarcoma
Ovarian germ cell tumour
Testicular germ cell tumour | Leoporelin
Early stage breast cancer
Metastatic breast cancer |

30 medicines previously included
allopurinol; asparaginase; bleomycin; calcium folinate; carboplatin; chlorambucil; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin; dexamethasone; docetaxel; doxorubicin; etoposide; fluorouracil; hydrocortisone; hydroxycarbamide; ifosfamide; mercaptopurine; mesna; methotrexate; methylprednisolone; paclitaxel; prednisolone; procarbazine; tamoxifen; thioguanine; vinblastine; vincristine

Children 5th edition

- | | |
|---|---|
| Bleomycin
Hodgkin lymphoma
Testicular germ cell tumour
Ovarian germ cell tumour | Ifosfamide
Osteosarcoma
Rhabdomyosarcoma
Ewing sarcoma
Testicular germ cell tumour
Ovarian germ cell tumour |
| Calcium Folate
Osteosarcoma
Burkitt lymphoma | Paclitaxel
Ovarian germ cell tumour |
| Carboplatin
Osteosarcoma
Burkitt lymphoma | Vinblastine
Testicular germ cell tumour
Ovarian germ cell tumour |
| Cisplatin
Osteosarcoma
Testicular germ cell tumour
Ovarian germ cell tumour | |
| Dacarbazine
Hodgkin lymphoma | |
| Etoposide
Retinoblastoma
Ewing sarcoma
Acute lymphoblastic leukemia
Burkitt lymphoma
Hodgkins lymphoma
Testicular germ cell tumour
Ovarian germ cell tumour | |
| Filgrastim
Primary and secondary prophylax. neutropenia
Chemotherapy facilitator | |

16 medicines previously included
allopurinol; asparaginase; cyclophosphamide; cytarabine; dactinomycin; dexamethasone; doxorubicin; daunorubicin; hydrocortisone; mercaptopurine; mesna; methotrexate; methylprednisolone; prednisolone; thioguanine; vincristine

SPECIAL THANKS

Special thanks to the nearly 100 volunteer experts who contributed from across the world



UICC would like to thank the Livestrong Foundation and National Cancer Institute USA, Centre for Global Health, for financial contributions to this work



For any questions, please contact:
map@uicc.org
www.uicc.org

UNION FOR INTERNATIONAL CANCER CONTROL
UNION INTERNATIONALE CONTRE LE CANCER
62 route de Frontenex, 1207 Geneva, Switzerland
Tel +41 (0)22 809 1811 Fax +41 (0)22 809 1810 Email info@uicc.org